The Conversation (0)
BrainStorm Receives US Patent Allowance for NurOwn Platform
Oct. 07, 2019 08:09AM PST
Biotech InvestingThe company received a notice of allowance for its US Patent Application called ‘Method of Qualifying Cells.’
BrainStorm Cell Therapeutics (NASDAQ:BCLI) has announced that the US Patent and Trademark Office has given a notice of allowance for its US Patent application number 15/113, 105.
As quoted in the press release:
The allowed claims cover a pharmaceutical composition for MSC-NTF cells secreting neurotrophic factors (NurOwn®) comprising a culture medium as a carrier and an isolated population of differentiated bone marrow-derived MSCs that secrete neurotrophic factors.
Patent families protecting NurOwn® have previously issued in the United States, Japan, Europe, Hong-Kong and Israel.
“This allowance further expands the patent protection of the NurOwn® Cellular Therapeutic Technology Platform and enables us to accelerate clinical development for new neurodegenerative indications,” commented BrainStorm President and CEO, Chaim Lebovits.